StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)

Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –

Neurocrine Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Neurocrine Biosciences's revenue for the twelve months ending Jun 30, 2026 was $3.37B, up 34.4% year over year. For fiscal 2025 it was $2.86B, up 21.4% from the year before. Over ten years it grew 64.5% a year on average. The highest annual figure on record is $2.86B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.86B+21.4%
FY2024Dec 31, 2024$2.36B+24.8%
FY2023Dec 31, 2023$1.89B+26.8%
FY2022Dec 31, 2022$1.49B+31.3%
FY2021Dec 31, 2021$1.13B+8.4%
FY2020Dec 31, 2020$1.05B+32.7%
FY2019Dec 31, 2019$788.10M+74.7%
FY2018Dec 31, 2018$451.20M+179.2%
FY2017Dec 31, 2017$161.63M+977.5%
FY2016Dec 31, 2016$15.00M-24.1%
FY2015Dec 31, 2015$19.77M–
FY2014Dec 31, 2014$0-100.0%
FY2013Dec 31, 2013$2.92M-94.5%
FY2012Dec 31, 2012$53.14M-31.4%
FY2011Dec 31, 2011$77.41M+131.1%
FY2010Dec 31, 2010$33.50M+1034.5%
FY2009Dec 31, 2009$2.95M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$959.00M+39.5%
Q1 FY2026Mar 31, 2026$814.50M+42.2%
Q4 FY2025Dec 31, 2025$805.50M+28.3%
Q3 FY2025Sep 30, 2025$794.90M+27.8%
Q2 FY2025Jun 30, 2025$687.50M+16.5%
Q1 FY2025Mar 31, 2025$572.60M+11.1%
Q4 FY2024Dec 31, 2024$627.70M+21.8%
Q3 FY2024Sep 30, 2024$622.10M+24.7%
Q2 FY2024Jun 30, 2024$590.20M+30.4%
Q1 FY2024Mar 31, 2024$515.30M+22.6%
Q4 FY2023Dec 31, 2023$515.20M+25.0%
Q3 FY2023Sep 30, 2023$498.80M+28.6%
Q2 FY2023Jun 30, 2023$452.70M+19.7%
Q1 FY2023Mar 31, 2023$420.40M+35.4%
Q4 FY2022Dec 31, 2022$412.00M+32.1%
Q3 FY2022Sep 30, 2022$387.90M+31.0%
Q2 FY2022Jun 30, 2022$378.20M+30.9%
Q1 FY2022Mar 31, 2022$310.60M+31.3%
Q4 FY2021Dec 31, 2021$312.00M+25.9%
Q3 FY2021Sep 30, 2021$296.00M+14.5%
Q2 FY2021Jun 30, 2021$288.90M-4.5%
Q1 FY2021Mar 31, 2021$236.60M-0.2%
Q4 FY2020Dec 31, 2020$247.90M+1.6%
Q3 FY2020Sep 30, 2020$258.50M+16.4%
Q2 FY2020Jun 30, 2020$302.40M+64.8%
Q1 FY2020Mar 31, 2020$237.10M+71.3%
Q4 FY2019Dec 31, 2019$244.10M+85.6%
Q3 FY2019Sep 30, 2019$222.10M+46.4%
Q2 FY2019Jun 30, 2019$183.50M+89.4%
Q1 FY2019Mar 31, 2019$138.40M+94.7%
Q4 FY2018Dec 31, 2018$131.49M+39.1%
Q3 FY2018Sep 30, 2018$151.76M+149.7%
Q2 FY2018Jun 30, 2018$96.91M+1429.7%
Q1 FY2018Mar 31, 2018$71.09M–
Q4 FY2017Dec 31, 2017$94.52M–
Q3 FY2017Sep 30, 2017$60.77M–
Q2 FY2017Jun 30, 2017$6.34M–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More Neurocrine Biosciences figures

See a number that looks wrong?